Kite, a Gilead company, says the US Food and Drug Administration (FDA) has approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland.
Image: https://www.biopharma-reporter.com
Kite, a Gilead company, says the US Food and Drug Administration (FDA) has approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland.
Image: https://www.biopharma-reporter.com
Biotechnology innovation is a team sport.
While we often credit the discovery of a promising new therapy to a single scientist or research team, turning that discovery into a viable product patients can access requires a vast network of players. There are manufacturing platforms capable of producing new cell and gene therapies, teams to support preclinical and clinical trials, real estate developers that offer cutting-edge laboratory space and experts across a wide range of fields who all contribute to bringing a product to market.
Montgomery County is well known for many transformative firsts in life sciences. First to sequence the human genome; first gene therapy for sickle cell, first cell therapy for COVID-19 — and that’s just the start.* Montgomery County is an epicenter for translating knowledge into life-changing treatment and cures, with gene and cell therapies representing some of the most promising advancements in human health.
Image: Being part of the industry that delivers building solutions to help scientists do their work is what drives Pat Larrabee, CEO of Facility Logix. – https://www.bizjournals.com
In biotechnology, speed matters.
Emerging technology has opened a new world of possibilities for treating — and potentially curing — diseases. Scientists are developing cell and gene therapies designed to help patients with cancer, heart disease, liver disease, Parkinson’s disease, Alzheimer’s and many other conditions. The faster they can get these therapies from the laboratory through clinical trials and into production, the sooner people will be able to benefit.
H
ome to nearly 18 federal agency headquarters, 36 federal labs, and more than 300 life science companies, it’s no surprise Maryland’s Montgomery County is a leader in the life sciences industry.
The six life sciences companies highlighted here consider Montgomery County critical to their success.
MaxCyte, Inc.
“The Montgomery County community has an expansive amount of experience and a perpetual abundance of innovative ideas based on excellent science,” says Doug Doerfler, CEO of MaxCyte, Inc. MaxCyte provides technologies to advance innovative cell-based research and next-generation cell therapeutics. The company’s Flow Electroporation® platform facilitates complex engineering of a wide variety of cells, currently focusing on immuno-oncology and gene editing.
Image: https://www.bizjournals.com
The D.C. government is hoping to receive significant federal funding to bring more of the region’s booming life sciences industry within District borders.
The District plans to apply for $92M to add research and innovation facilities to four major health institutions, Mayor Muriel Bowser and the Office of the Deputy Mayor for Planning and Economic Development announced Thursday
Image: Bisnow/Jacob Wallace
Deputy Mayor John Falcicchio speaks during a panel at Bisnow’s The Future of Downtown D.C. & The Golden Triangle event on March 31, 2022.
RIVERDALE, Md., April 26, 2022 /PRNewswire/ — Medcura, Inc., a commercial-stage medical device company, today announced the expansion of its senior management team to include Dr. Kenneth Renkens as its Chief Medical Officer. Dr. Renkens is a thought-leading neurosurgeon who co-founded the Indiana Spine Group and has been involved in the development and commercial success of numerous innovative products now widely used in operating rooms around the world.
Chosen for his deep expertise in neurosurgery and past involvement with numerous implantable surgical innovations, Dr. Renkens joins an experienced team with a demonstrated track record of execution in delivering groundbreaking hemostat innovations. The Medcura team is now narrowly focusing its attention on bringing more disruptive technology to the Operating Room (OR).
T
op companies in the life sciences industry choose to locate in Virginia – and flourish here – because of the state’s top talent, advanced culture of innovation, outstanding logistical advantages, competitive costs, and top-ranked business climate. Virginia’s life sciences sector has gained significant momentum in recent years, with 20 life sciences industry projects announced in just the past three years, representing over 1,400 jobs and $1.2 billion in investment. Recent announcements include U.S. Pharmacopeia, AMPAC, Civica, Merck, GlaxoSmithKline (GSK), Bausch + Lomb, and Virginia-grown biotech firm Grenova.
Image: https://www.linkedin.com/
RIVERDALE, Md., April 26, 2022 /PRNewswire/ — Medcura, Inc., a commercial-stage medical device company, today announced the expansion of its senior management team to include Dr. Kenneth Renkens as its Chief Medical Officer. Dr. Renkens is a thought-leading neurosurgeon who co-founded the Indiana Spine Group and has been involved in the development and commercial success of numerous innovative products now widely used in operating rooms around the world.
Chosen for his deep expertise in neurosurgery and past involvement with numerous implantable surgical innovations, Dr. Renkens joins an experienced team with a demonstrated track record of execution in delivering groundbreaking hemostat innovations. The Medcura team is now narrowly focusing its attention on bringing more disruptive technology to the Operating Room (OR).
Image: https://biobuzz.io
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Casimir’s research on the development of the Duchenne Video Assessment (DVA) scorecards was published in PLOS ONE. Emmes acquired Casimir in March 2022, and the group is now part of Emmes’ Rare Disease Center, Orphan Reach™.
The DVA is a novel, home-based clinical outcome assessment that measures ease of movement among those with Duchenne muscular dystrophy (DMD) through identification of compensatory movement patterns. Caregivers video record patients performing specific movement tasks at home using a secure mobile application. The paper describes the development of the scorecards that DVA-trained physical therapists use to score the videos.